Company Profile
Pell Bio-Med Technology Co., Ltd., a biomedical company provides the research, development, manufacturing, and sales of chimeric antigen recombinant T cell (CAR-T), and other related services and products.
It offers autologous adipose-derived stem cell (ADSC) products to treat osteoarthritis and cartilage defects in the knee. Its portfolio also includes cytokine-induced Killer cells to treat various tumors, and dendritic cell-activated cytokine-induced killer to treat solid tumors.
The company is also involved in the phase 1/2 multicenter study to evaluate the safety and efficacy of CD19-targeted chimeric antigen receptor T-cell therapy in patients with relapsed or refractory B-cell lymphoma A follow-up study of lentiviral-based gene-modified immune cell therapy. Founded in 2017, the company is based in Taipei, Taiwan.